Med-IQ Webcast Reviews Staging Strategies for Hepatocellular Carcinoma

BALTIMORE, MD—December 11, 2014—Accurate staging is a crucial factor in determining the probability of survival for patients with hepatocellular carcinoma (HCC) and in guiding patient management decisions. Although several staging systems have been proposed, no consensus exists regarding the optimal staging algorithm. To help clinicians improve their management of patients with HCC, Med-IQ, an ACCME-accredited provider of continuing medical education (CME), has provided this complimentary CME Webcast, Changing Science and Future Pathways in the Management of Hepatocellular Carcinoma: A Multidisciplinary Perspective.

Hepatologists, oncologists, and oncology nurses are encouraged to join faculty in this free, educational activity—expiring soon—as it aims to integrate clinical evidence with expert insights into the contexts of real-world case scenarios. Participants will gain insight into the rationale for staging HCC and how it affects selecting therapeutic interventions that align with disease stages and addressing disease symptoms.

Evaluating staging strategies is especially important for patients who are considered to be candidates for systemic therapy, of which nearly 50% of all patients with HCC are. In addition to reviewing staging tools, Dr. Abou-Alfa and Dr. Barton-Burke discuss targeted therapies and address disease symptoms and treatment-related side effects in this Webcast.

Clinicians are invited to visit www.med-iq.com/a768 for complimentary access to this educational opportunity before it expires on 12/19/14. For more information, please call (toll-free) 866 858 7434 or e-mail info@med-iq.com.

This activity is approved for AMA PRA Category 1 Credit™ .

Med-IQ is accredited by the California Board of Registered Nursing to provide continuing education to nurses. Provider approved by the California Board of Registered Nursing, provider number CEP 14745, for 1.0 contact hour.

This activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals.

About Med-IQ

Med-IQ, America's most respected provider of continuing medical education (CME), inspires healthcare professionals through award-winning activities that deliver sophisticated outcomes-based educational designs with measurable results in professional competence and performance. Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the California Board of Registered Nursing (CBRN), and the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing medical education to physicians, nurses, and pharmacists, respectively.

As a leader in the CME industry, Med-IQ has delivered 32 performance improvement (PI) and quality improvement (QI) initiatives that make use of systems-based training such as Crew Resource Management (CRM) to improve team performance and patient outcomes. These initiatives have achieved improvement in healthcare professional performance, quality of care, and patient outcomes. Med-IQ's work in this space has been published 27 times in peer-reviewed journals, and the company has been recognized by the Alliance for Continuing Education in the Health Professions for excellence in CE research (William Campbell Felch Award 2013, 2011), educational collaborations (2013), outstanding CME outcomes assessment (2012), and exceptional leadership (Leadership Award 2013, President’s Award 2012). To learn more about Med-IQ, visit www.Med-IQ.com, like us on Facebook, follow us on Twitter, and connect with us on LinkedIn.

For more information, contact:

Amy Caswell
Senior Audience Development Manager
Med-IQ
866 858 7434
info@med-iq.com


Med-IQ.
Inspiring Medical Education.